Last updated: September 28, 2026
sfRowasa is the sulfite-free mesalamine rectal suspension enema, typically supplied as 4 g per 60 mL. Its commercial profile is that of a mature, niche small-molecule product for ulcerative colitis. The product has no meaningful remaining regulatory exclusivity, faces generic competition, and is not reported as a separately material revenue line by its commercial owner. Its value is concentrated in brand recognition, physician familiarity, supply reliability, and residual demand among patients who require rectal mesalamine and cannot tolerate sulfite-containing alternatives.
What is sfRowasa and what market does it serve?
sfRowasa contains mesalamine, also called 5-aminosalicylic acid or 5-ASA. The product is administered rectally as a suspension enema and is used for the treatment of active ulcerative proctitis, proctosigmoiditis, and left-sided ulcerative colitis.
Product profile
| Attribute |
sfRowasa profile |
| Active ingredient |
Mesalamine |
| Dosage form |
Rectal suspension enema |
| Common strength |
4 g per 60 mL |
| Therapeutic area |
Inflammatory bowel disease |
| Primary indication |
Distal ulcerative colitis |
| Regulatory category |
Prescription small-molecule drug |
| Reference product |
Rowasa/sfRowasa mesalamine enema product family |
| Commercial maturity |
Mature, post-exclusivity |
| Biosimilar exposure |
None |
| Main competitive threat |
Generic mesalamine enemas and alternative rectal 5-ASA products |
The sulfite-free formulation differentiates sfRowasa from older mesalamine enemas that contain sulfites or other excipients that may cause tolerability concerns for some patients. That distinction supports continued niche demand but does not create strong market exclusivity once equivalent generic products are available.
What is the FDA regulatory status of sfRowasa?
sfRowasa is an FDA-approved prescription drug marketed through the 505(b)(1) new drug application framework. Its approval predates the current commercial market for generic mesalamine enemas by many years.
The product is not a biologic and does not qualify for biosimilar exclusivity. Its relevant competitive pathway is abbreviated new drug application, or ANDA, approval for generic mesalamine rectal suspension products.
FDA market position
The principal regulatory facts are:
- sfRowasa is a legacy mesalamine product.
- Its approval is well beyond the five-year new chemical entity exclusivity period.
- Any pediatric exclusivity associated with the product would have expired long ago.
- The product is exposed to ANDA-based generic competition.
- The market does not depend on a pending regulatory exclusivity event.
The FDA Orange Book remains the controlling public source for listed patents, regulatory exclusivity, therapeutic-equivalence codes, and approved dosage forms.[1] For a mature product such as sfRowasa, commercial risk is driven less by regulatory approval and more by generic availability, wholesaler stocking, payer coverage, and manufacturing continuity.
What patents protect sfRowasa?
No material unexpired patent estate is publicly associated with the core sfRowasa product in the way that a newer branded drug would be protected.
Patent estate assessment
| Patent category |
Current commercial relevance |
| Mesalamine composition patents |
Expired or commercially obsolete |
| Original rectal-delivery patents |
Expired or unlikely to block current generic entry |
| Sulfite-free formulation patents |
No publicly evident blocking estate with material market effect |
| Method-of-use patents |
No known active patent barrier that prevents generic mesalamine enema use |
| Manufacturing patents |
Potentially relevant to individual suppliers, but not a broad sfRowasa exclusivity barrier |
| Orange Book-listed patents |
No known active listing that supports meaningful brand exclusivity |
The original intellectual-property position was likely built around mesalamine chemistry, rectal suspension formulation, and treatment of distal ulcerative colitis. Those rights are too old to support present-day market protection. The commercial issue is therefore not whether the brand has a defensible patent monopoly. It does not. The issue is whether generic manufacturers can supply a therapeutically equivalent product consistently.
What formulations are protected by sfRowasa?
The principal formulation distinction is the sulfite-free rectal suspension. The product uses a liquid suspension delivered through a rectal enema applicator. The formulation can create practical barriers related to suspension uniformity, container compatibility, dose delivery, microbial control, and manufacturing scale.
Those barriers may raise development and quality-control costs. They do not necessarily create enforceable market exclusivity. Generic manufacturers can compete by demonstrating pharmaceutical equivalence, bioequivalence where applicable, and compliance with FDA quality requirements.
When did sfRowasa lose exclusivity?
sfRowasa lost meaningful regulatory exclusivity many years ago. The drug is not in the period in which a sponsor can prevent ANDA approval through new chemical entity, orphan-drug, or standard new-product exclusivity.
Exclusivity timeline
| Milestone |
Market implication |
| Original FDA approval |
Established the branded mesalamine enema market |
| Five-year NCE exclusivity |
Expired decades ago |
| Original formulation and use patents |
No longer a practical barrier to generic entry |
| ANDA approvals |
Enabled generic substitution |
| Current status |
Mature, genericized prescription market |
The relevant launch question is not "when does sfRowasa lose exclusivity?" It already has. The relevant question is whether a generic manufacturer can maintain supply and obtain favorable payer placement.
Which companies are challenging sfRowasa?
Generic drug manufacturers challenge sfRowasa through ANDA filings rather than patent litigation directed at a valuable active patent estate. Publicly visible competition has developed around mesalamine 4 g/60 mL rectal suspension enemas and therapeutically equivalent products.
The competitive field can include:
- Generic manufacturers with approved mesalamine enema ANDAs.
- Contract manufacturers supplying private-label or authorized-generic channels.
- Branded manufacturers selling alternative rectal mesalamine formulations.
- Manufacturers of mesalamine suppositories and rectal foam.
- Oral mesalamine manufacturers competing for the same ulcerative-colitis treatment budget.
Are there Paragraph IV challenges to sfRowasa?
Paragraph IV litigation is not the main current risk profile for sfRowasa. Paragraph IV certifications matter when a generic applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For an old mesalamine enema with no apparent blocking patent estate, generic entry is more consistent with ordinary ANDA approval and therapeutic-equivalence substitution than with a high-value Paragraph IV dispute.
A historical Paragraph IV filing could have occurred during the initial genericization period, but it would not materially alter the current market conclusion without an active patent, litigation judgment, or settlement restricting entry. No such active restriction is evident in the public market profile.
What patent litigation affects sfRowasa?
There is no publicly prominent, currently material patent litigation affecting sfRowasa comparable to litigation surrounding high-value specialty drugs.
Litigation status
| Litigation issue |
Current assessment |
| Active Orange Book patent enforcement |
No material current barrier identified |
| Paragraph IV injunction |
No publicly evident continuing injunction |
| Settlement agreement limiting generic entry |
No publicly evident active restriction |
| Antitrust or reverse-payment exposure |
Not a central current issue |
| Product-liability litigation |
Separate from patent exclusivity and not determinative of generic entry |
Any historical litigation involving mesalamine products should be analyzed separately from current sfRowasa exclusivity. Old patent settlements generally lose commercial importance after the relevant patents expire and multiple generic suppliers enter the market.
How strong is the sfRowasa patent estate?
The patent estate is weak from a present-day commercial perspective.
Its residual strength is limited to three areas:
- Brand and trade-name recognition.
- Potential know-how relating to suspension manufacture and packaging.
- Supply-chain relationships with wholesalers, pharmacies, and specialty distributors.
Those assets can support continued sales but do not prevent generic substitution. The product’s value is therefore operational rather than patent-driven.
Manufacturing and intellectual-property barriers
Mesalamine itself is a well-established active pharmaceutical ingredient. The technical challenges are more likely to involve:
- Stable dispersion of mesalamine particles.
- Consistent delivered dose from a 60 mL enema.
- Suspension homogeneity during filling and use.
- Container and applicator compatibility.
- Microbiological quality.
- Shelf-life and storage performance.
- Reliable API sourcing.
These issues may delay or complicate generic production. They are not equivalent to patent protection. A manufacturer that solves the technical and regulatory requirements can compete without acquiring the originator’s intellectual property.
How does sfRowasa compare with competing mesalamine products?
| Product category |
Commercial advantage |
Commercial disadvantage |
| sfRowasa enema |
Sulfite-free formulation and established physician familiarity |
Generic competition; inconvenient administration |
| Generic mesalamine enema |
Lower price and payer preference |
Supply variability; limited brand differentiation |
| Mesalamine suppository |
Convenient for rectal disease near the anus and rectum |
Less suitable for more proximal left-sided disease |
| Mesalamine rectal foam |
Easier administration for some patients |
Often higher cost and different coverage dynamics |
| Oral mesalamine |
Broad utility and easier administration |
May be less targeted for distal disease; systemic exposure |
| Corticosteroid rectal products |
Useful for active inflammation |
Different safety and maintenance profiles |
| Budesonide rectal foam |
Local anti-inflammatory alternative |
Higher cost and steroid-related treatment limitations |
sfRowasa occupies a narrow segment: patients requiring topical mesalamine for distal ulcerative colitis who prefer or tolerate an enema and may value the sulfite-free formulation.
What is the financial trajectory for sfRowasa?
sfRowasa’s financial trajectory is best characterized as mature, declining, and strategically non-core unless the product retains a strong price premium or faces limited generic supply.
Revenue exposure
The commercial owner does not publicly report sfRowasa as a separate material revenue line in its standard financial disclosures. Bausch Health and its Salix business report revenue at broader product and segment levels rather than disclosing a standalone sfRowasa income statement.[2]
That prevents a reliable public calculation of:
- Annual sfRowasa net sales.
- Gross-to-net discounting.
- Product-level operating margin.
- Prescription volume.
- Market share by payer channel.
- Revenue contribution relative to Xifaxan, Trulance, or other Salix products.
The product is unlikely to be a material driver of consolidated pharmaceutical-company valuation. Its financial importance is more likely to arise from incremental cash contribution, portfolio completeness, and the value of maintaining a niche product with established demand.
Likely commercial trajectory
| Period |
Expected market dynamic |
| Historical branded period |
Premium pricing supported by brand status and limited alternatives |
| Initial generic entry |
Rapid price and share pressure |
| Mature generic period |
Lower average selling price and fragmented supply |
| Current period |
Niche demand, limited growth, operational focus |
| Forward outlook |
Stable-to-declining volume with potential price erosion |
Revenue can remain relatively resilient if patients and prescribers specifically prefer the sulfite-free product, if generic supply is intermittent, or if payers do not aggressively substitute. Those factors can preserve a branded niche without restoring monopoly economics.
What generic launch risks exist for sfRowasa?
Generic launch risk is high in principle because the product is old and lacks meaningful exclusivity. The principal barriers are commercial and technical rather than legal.
Generic entry scenarios
| Scenario |
Impact on sfRowasa |
| Multiple reliable generic suppliers |
Significant price erosion and rapid substitution |
| One or two generic suppliers |
Continued brand demand if shortages or payer exceptions occur |
| Generic manufacturing disruption |
Temporary branded volume recovery |
| Payer-imposed mandatory substitution |
Sharp decline in brand prescriptions |
| Product discontinuation by a generic supplier |
Potential short-term pricing support for remaining suppliers |
| Continued physician preference |
Slower erosion but no restoration of exclusivity |
The most plausible long-term scenario is a low-growth or declining market with periodic supply-driven volatility.
What is the geographic coverage of sfRowasa?
sfRowasa is primarily relevant to the U.S. prescription market. Its commercial position depends on FDA approval, U.S. Orange Book status, domestic distribution, and American payer reimbursement.
International mesalamine enema markets may use different brand names, formulations, labeling, and regulatory standards. U.S. patent and exclusivity conclusions should not be extended automatically to Europe, Canada, Japan, or emerging markets. Geographic value is likely limited by the mature nature of mesalamine therapy and the availability of local generic products.
How does sfRowasa compare with newer ulcerative-colitis drugs?
sfRowasa competes in a low-cost, localized-treatment segment, while newer ulcerative-colitis therapies compete in moderate-to-severe disease and systemic treatment.
| Therapy class |
Relative role |
| Mesalamine enema |
Local treatment for distal disease |
| Oral mesalamine |
First-line or maintenance treatment across broader disease areas |
| Corticosteroids |
Induction treatment, not preferred for long-term maintenance |
| Biologics |
Moderate-to-severe disease |
| JAK inhibitors |
Moderate-to-severe disease after or alongside other therapies |
| S1P modulators and targeted agents |
Advanced systemic treatment |
Biologics and targeted small molecules create no direct biosimilar risk for sfRowasa. Their effect is indirect: improved systemic treatment options can reduce the need for topical mesalamine in patients with more extensive or refractory disease.
Key Takeaways
- sfRowasa is a mature sulfite-free mesalamine rectal suspension enema for distal ulcerative colitis.
- Its regulatory and patent exclusivity expired long ago.
- Generic mesalamine enemas, rectal suppositories, rectal foam, and oral mesalamine are the main competitive alternatives.
- No active patent estate or litigation appears to create a meaningful current barrier to generic entry.
- Product-level revenue is not separately disclosed by the commercial owner.
- The financial trajectory is mature to declining, with value driven by residual demand, formulation preference, supply reliability, and payer behavior.
- The main commercial risk is generic substitution, not biosimilar competition or patent invalidation.
- Manufacturing know-how may support quality and supply differentiation, but it does not replace enforceable exclusivity.
FAQs About sfRowasa Patent and Market Exposure
Is sfRowasa still protected by patents?
No material current patent protection appears to block generic mesalamine enema competition. Any original composition, formulation, or use patents are too old to provide meaningful present-day exclusivity.
Is sfRowasa a biologic eligible for biosimilar competition?
No. sfRowasa is a conventional small-molecule mesalamine product. Its competitors use the ANDA generic-drug pathway, not the biosimilar pathway.
Does sfRowasa have a separate Orange Book exclusivity period?
No current exclusivity period materially protects the product. The Orange Book is relevant for confirming any listed patents, therapeutic-equivalence information, and approved generic products.[1]
Can a generic company launch mesalamine enema without sfRowasa patent litigation?
Yes, assuming the generic applicant satisfies FDA requirements and no enforceable listed patent blocks approval. The product’s current market profile is consistent with generic competition rather than an active patent-enforcement strategy.
Is sfRowasa financially material to Bausch Health?
Public financial reporting does not identify sfRowasa as a separately material revenue contributor. Its value is likely limited relative to Bausch Health’s larger pharmaceutical brands and therapeutic franchises.[2]
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Bausch Health Companies Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.bausch.com/financial-information/sec-filings
